Q-omics provides the consensus-scored VIPAS39 profile across patient tissues and cancer cell-line models. VIPAS39 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, VIPAS39 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, VIPAS39 RNA expression shows 19,419 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, HNSC, and ACC as cancer lineages where VIPAS39 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VIPAS39 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VIPAS39 survival associations across molecular data types. VIPAS39 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VIPAS39 RNA expression–survival associations across cancer types. High VIPAS39 expression shows unfavorable associations in BLCA, ACC, MESO and STAD, but favorable associations in KIRC and SCLC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for VIPAS39 RNA expression.
This table summarizes VIPAS39 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for VIPAS39. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VIPAS39 shows higher tumor expression in HNSC, KIRP, BLCA, LIHC, LUAD and CHOL. The HNSC box plot shows higher VIPAS39 RNA expression in tumor versus normal tissue (log2 FC = +1.006, t-test p < 0.001).
This table shows molecular features associated with VIPAS39 in patient tissues and cancer cell lines. In patient samples, VIPAS39 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, VIPAS39 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
